Why CVS stopped sharing sales data on its leading Humira biosimilarnews2025-07-22T18:27:42+00:00July 22nd, 2025|Endpoints News|
Sanofi to buy early-stage vaccine maker Vicebio for $1.15B upfrontnews2025-07-22T05:30:33+00:00July 22nd, 2025|Endpoints News|
Sarepta halts US shipments of Duchenne therapy, bowing to FDAnews2025-07-22T00:33:19+00:00July 22nd, 2025|Endpoints News|
AstraZeneca pledges $50B in US manufacturing, R&D expansionnews2025-07-21T21:54:23+00:00July 21st, 2025|Endpoints News|
FDA threatens to use ‘full regulatory authority’ against Sareptanews2025-07-21T18:48:20+00:00July 21st, 2025|Endpoints News|
FDA’s continued approval of mRNA shots is infuriating some in MAHAnews2025-07-21T18:29:22+00:00July 21st, 2025|Endpoints News|
Biogen invests $2B to expand two campuses in North Carolina news2025-07-21T16:18:24+00:00July 21st, 2025|Endpoints News|
Updated: FDA names former industry exec Tidmarsh as next CDER directornews2025-07-21T11:42:39+00:00July 21st, 2025|Endpoints News|
Alkermes gets a mid-stage narcolepsy hit, but trails Takeda in R&D racenews2025-07-21T10:07:25+00:00July 21st, 2025|Endpoints News|
FDA adcomm votes against Otsuka’s Rexulti-Zoloft combo for PTSDnews2025-07-18T20:00:23+00:00July 18th, 2025|Endpoints News|
